RT Journal Article SR Electronic T1 Covid-19 Vaccine Acceptance Among People Incarcerated in Connecticut State Jails JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.05.19.22275339 DO 10.1101/2022.05.19.22275339 A1 Lind, Margaret L. A1 Kennedy, Byron S. A1 Nieto, Murilo Dorion A1 Houde, Amy J. A1 Sosensky, Peri A1 Borg, Ryan A1 Cummings, Derek A.T. A1 Ko, Albert I. A1 Richeson, Robert P. YR 2022 UL http://medrxiv.org/content/early/2022/05/20/2022.05.19.22275339.abstract AB Objective To assess the Connecticut Department of Correction’s (DOC) COVID-19 vaccine program within jails.Methods We conducted a retrospective cohort analysis among people who were incarcerated in a DOC-operated jail between February 2 and November 8, 2021, and were eligible for vaccination at the time of incarceration (intake). We compared the vaccination rates before and after incarceration using an age-adjusted survival analysis with a time-varying exposure of incarceration and an outcome of vaccination.Results During the study period, 3,716 people spent ≥1 night in jail and were eligible for vaccination at intake. Of these residents, 136 were vaccinated prior to incarceration, 2,265 had a recorded vaccine offer, and 476 were vaccinated while incarcerated. The age-adjusted hazard of vaccination following incarceration was significantly higher than prior to incarceration (12.5; 95% CI: 10.2-15.3).Conclusions We found that residents were more likely to become vaccinated in jail than the community. Though these findings highlight the utility of vaccination programs within jails, the low level of vaccination in this population speaks to the need for additional program development within jails and the community.Competing Interest StatementA.I.K serves as an expert panel member for Reckitt Global Hygiene Institute, scientific advisory board member for Revelar Biotherapeutics and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals, and has received grants from Merck, Regeneron Pharmaceuticals and Tata Medical and Diagnostics for research related to COVID-19, all of which are outside the scope of the submitted work. Other authors declare no conflict of interest.Funding StatementConnecticut Department of Public Health Emerging Infections Program (EIP): COVID-19 contract (DPH log # 2021-0071-3)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was determined to be a public health surveillance activity by the Yale University Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study belongs to the Connecticut Department of Correction. Qualified researchers may submit a data share request for de-identified patient level data by contacting the corresponding author with a detailed description of the research question.